Format

Send to

Choose Destination
Chem Pharm Bull (Tokyo). 1990 Jun;38(6):1790-2.

Inhibition of angiogenesis by bleomycin and its copper complex.

Author information

1
Division of Cancer Therapeutics, Tokyo Metropolitan Institute of Medical Science, Japan.

Abstract

The effects of bleomycin (BLM) and its copper complex on embryonic angiogenesis were studied in the chorioallantoic membranes of 4.5-day-old chick embryos. Copper-free BLM inhibited embryonic angiogenesis in a dose-dependent manner, with activity detectable at 1 ng/egg and maximal at 1000 ng/egg. Also, treatment with copper-BLM complex dose-dependently caused inhibition of embryonic angiogenesis in a lower dose range. Since tumor growth is believed to depend on angiogenesis, the present results may indicate that the antiangiogenic activity of BLM is, at least in part, implicated in the antitumor activity of the drug.

PMID:
1698565
DOI:
10.1248/cpb.38.1790
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center